Cognitive Effects of Epilepsy & ASMs
Cognitive impairment is one of the most important and underrecognized consequences of epilepsy, affecting educational attainment, employment, quality of life, and independence. Multiple factors converge to impact cognition in people with epilepsy: the underlying etiology, seizure type and frequency, interictal epileptiform discharges, antiseizure medication (ASM) effects, psychiatric comorbidities, sleep disturbance, and psychosocial stress. Neuropsychological testing provides an objective assessment of cognitive function and is essential for surgical planning, monitoring treatment effects, and guiding rehabilitation. Understanding which ASMs have the greatest cognitive burden — and which are cognitively favorable — is a critical skill for the practicing neurologist.
Bottom Line
- Topiramate has the most significant adverse cognitive effects of any commonly used ASM, particularly affecting word-finding, verbal fluency, processing speed, and working memory — effects are dose-dependent and may persist even at low doses
- Phenobarbital, benzodiazepines, and phenytoin significantly impair attention, processing speed, and memory; chronic phenytoin use is associated with cerebellar atrophy
- Lamotrigine and levetiracetam have the most favorable cognitive profiles; lacosamide and gabapentin also have minimal cognitive impact
- Patients often do not notice ASM-related cognitive impairment until the offending drug is withdrawn — objective neuropsychological testing reveals deficits missed by subjective report
- Polytherapy compounds cognitive effects more than monotherapy, independent of specific drug choice
- Epilepsy surgery can improve overall cognition by eliminating seizures and reducing ASM burden, but carries specific risks (e.g., verbal memory decline after dominant-hemisphere anterior temporal lobectomy)
- Epilepsy is an independent risk factor for dementia — recurrent seizures, status epilepticus, and hippocampal damage accelerate neurodegeneration
Factors Affecting Cognition in Epilepsy
The neuropsychological formulation in epilepsy recognizes that cognitive function is determined by the interplay of multiple factors. These can be broadly categorized into disease-related factors, treatment-related factors, and psychosocial factors. A comprehensive cognitive assessment must account for all of these contributors rather than attributing cognitive complaints solely to ASM effects or seizure activity.
| Category | Factor | Cognitive Impact | Examples |
|---|---|---|---|
| Disease-related | Underlying etiology | Structural lesions, genetic conditions, and neurodevelopmental disorders directly affect cognition | Hippocampal sclerosis → memory impairment; cortical dysplasia → variable deficits; DEE syndromes → intellectual disability |
| Seizure type & frequency | Recurrent generalized tonic-clonic seizures and status epilepticus cause cumulative injury; focal seizures may cause transient deficits in the involved network | Recurrent GTC → progressive hippocampal atrophy; NCSE → prolonged encephalopathy | |
| Epileptiform discharges | Interictal epileptiform discharges (IEDs) can cause "transient cognitive impairment" (TCI) even without clinical seizures | Left temporal IEDs → transient verbal memory impairment; frontal IEDs → attentional lapses | |
| Duration of epilepsy | Longer duration is associated with progressive cognitive decline, possibly from cumulative seizure damage and network disruption | 20+ years of temporal lobe epilepsy → progressive memory decline | |
| Age of onset | Earlier onset disrupts brain development; seizures during critical periods impair cognitive trajectories | Childhood-onset epilepsy → lower educational attainment; neonatal seizures → developmental delay | |
| Treatment-related | ASM effects | Drug-specific cognitive profiles; dose-dependent; cumulative with polytherapy | Topiramate → word-finding; phenobarbital → sedation/inattention; see ASM table below |
| Epilepsy surgery | Can improve cognition by eliminating seizures, but carries localization-specific risks | Dominant ATL → verbal memory decline; nondominant ATL → visual memory decline | |
| Psychosocial | Depression & anxiety | Independently impair attention, concentration, processing speed, and memory; effects may be confused with ASM side effects | PHQ-9 ≥10 correlates with measurable cognitive decline on neuropsychological testing |
| Sleep disruption | Seizures disrupt sleep architecture; OSA is more prevalent in epilepsy; poor sleep impairs consolidation | Nocturnal seizures → sleep fragmentation → daytime cognitive impairment | |
| Social and educational | Stigma, social isolation, limited educational opportunities, and underemployment | Reduced cognitive reserve; lower baseline performance on standardized testing |
ASM Cognitive Effects
Overview
All ASMs have the potential to affect cognition, but the magnitude varies enormously. The primary cognitive effects of ASMs involve attention, vigilance, and psychomotor speed — domains that form the foundation for higher-order cognitive functions. Secondary effects manifest as impairments in memory, language, and executive function. Critically, research demonstrates that patients are unreliable when reporting the presence or absence of ASM-related cognitive effects — many patients only recognize the cognitive burden of an ASM after it is withdrawn. Objective neuropsychological testing is therefore essential for accurate assessment.
| ASM | Cognitive Profile | Key Domains Affected | Dose-Dependence | Clinical Notes |
|---|---|---|---|---|
| Topiramate | Most significant cognitive impairment of any commonly used ASM | Verbal fluency (word-finding), processing speed, working memory, attention | Strong — effects increase above 200 mg/day; may occur at any dose | Randomized trial (Loring et al.) showed dose-dependent cognitive decline; effects may persist months after discontinuation; "cognitive reawakening" reported after withdrawal even after 16 years |
| Phenobarbital | Significant impairment across multiple domains | Attention, processing speed, memory consolidation, fine motor speed | Yes | Sedation compounds cognitive effects; particularly problematic in elderly and children; may impair learning in children |
| Benzodiazepines | Significant acute and chronic effects | Attention, short-term memory, psychomotor speed, visuospatial processing | Yes | Tolerance to sedation develops but cognitive effects may persist; long-term use associated with increased dementia risk |
| Phenytoin | Moderate impairment; chronic effects on cerebellum | Processing speed, motor speed, attention; chronic use → cerebellar dysfunction | Yes — toxicity at supratherapeutic levels causes significant impairment | Cerebellar atrophy with chronic use (independent of toxicity episodes); nystagmus and ataxia precede overt cognitive complaints |
| Zonisamide | Moderate — similar mechanism to topiramate (CA inhibitor) | Verbal fluency, processing speed | Yes | Cognitive effects are generally milder than topiramate but still clinically significant |
| Valproate | Mild to moderate | Processing speed; less effect on language; tremor may impair writing tasks | Yes | Tremor is the most common complaint; may mimic or worsen parkinsonism in elderly |
| Carbamazepine | Mild to moderate | Attention, processing speed; at therapeutic levels, effects are modest | Yes | Cognitive effects are generally less than phenytoin; diplopia and dizziness may affect performance |
| Oxcarbazepine | Mild | Processing speed (less than carbamazepine) | Mild | Better cognitive profile than carbamazepine; hyponatremia in elderly may cause confusion |
| Levetiracetam | Minimal or none | No consistent cognitive impairment | No | Behavioral effects (irritability, depression) may indirectly affect cognitive performance through mood |
| Lamotrigine | Minimal or none; possible mild benefit | No consistent impairment; may improve attention and processing speed (mood effect) | No | Best cognitive profile among all ASMs; preferred in patients with cognitive vulnerability; SANAD-II supports as first-line |
| Lacosamide | Minimal | No significant cognitive effects at therapeutic doses | Mild at high doses | Well tolerated cognitively; useful in elderly and patients with cognitive concerns |
| Gabapentin/Pregabalin | Minimal direct cognitive effect; sedation may impair | Sedation-related attentional effects; no specific language or memory impairment | Dose-related sedation | Cognitive effects primarily secondary to sedation; less concerning than topiramate or phenobarbital |
Polytherapy & Cognitive Risk
- The total number of ASMs is an independent predictor of cognitive impairment, regardless of which specific drugs are used
- A 2024 study found that cognitive impairment measured by MoCA and event-related potentials (ERPs) worsened significantly at 2 months after initiating carbamazepine, zonisamide, valproic acid, or topiramate — with topiramate showing the poorest recovery
- Combination of two cognitively impairing ASMs (e.g., topiramate + phenobarbital) produces synergistic rather than additive cognitive harm
- When cognitive complaints arise, simplify the ASM regimen before assuming the cognitive decline is disease-related
- The goal should always be monotherapy at the lowest effective dose when possible
Neuropsychological Testing
When to Refer
Neuropsychological testing provides a standardized, objective assessment of cognitive function across multiple domains. It is particularly valuable in epilepsy because subjective cognitive complaints often do not correlate with objective performance, and conversely, significant deficits may go unnoticed by the patient. Formal testing should be considered in the following situations:
- Presurgical evaluation: Required for all epilepsy surgery candidates to establish baseline cognitive function, lateralize language and memory, and predict postoperative risk
- Subjective cognitive complaints: When a patient reports word-finding difficulty, memory impairment, or "brain fog" — to distinguish ASM effects from disease progression, depression, or other causes
- ASM change: Before and after switching or adding an ASM to objectively document cognitive effects
- Progressive cognitive decline: To differentiate seizure-related cognitive deterioration from comorbid neurodegenerative disease
- Educational/occupational difficulties: In children and young adults with epilepsy struggling academically or professionally
- Medico-legal purposes: Disability determinations, fitness for duty assessments, driving evaluations
Domains Assessed
| Cognitive Domain | Common Tests | Clinical Relevance in Epilepsy |
|---|---|---|
| General intelligence | WAIS-IV (Full-Scale IQ) | Baseline intellectual functioning; premorbid estimate; discrepancy analysis |
| Verbal memory | CVLT-3, WMS-IV Logical Memory, RAVLT | Hippocampal integrity; dominant temporal lobe function; surgical risk prediction |
| Visual memory | BVMT-R, WMS-IV Visual Reproduction, Rey Complex Figure (delayed recall) | Nondominant temporal lobe function; visual/spatial memory |
| Language | BNT (naming), COWAT (verbal fluency), Token Test (comprehension) | Dominant hemisphere function; topiramate effects (word-finding); surgical risk |
| Attention & processing speed | Trail Making Test A & B, WAIS-IV Processing Speed Index, Stroop Test | Most sensitive to ASM effects; frontal/subcortical dysfunction |
| Executive function | Wisconsin Card Sorting Test, Tower of London, Verbal fluency (FAS) | Frontal lobe epilepsy; polytherapy effects; functional capacity |
| Motor function | Finger Tapping, Grooved Pegboard | Lateralizing value; ASM effects on motor speed; cerebellar dysfunction (phenytoin) |
| Mood & validity | BDI-II, BAI, MMPI-3, performance validity tests (TOMM, WMT) | Psychiatric comorbidities affecting cognition; malingering detection; medico-legal validity |
Epilepsy Surgery & Cognition
Cognitive Outcomes After Temporal Lobe Surgery
Anterior temporal lobectomy (ATL) remains the most commonly performed epilepsy surgery and achieves seizure freedom in 60–80% of patients. However, it carries specific cognitive risks that depend on the side of resection, the functional integrity of the tissue being removed, and the patient's preoperative cognitive baseline.
Cognitive Risks of Anterior Temporal Lobectomy
- Dominant (usually left) ATL: 30–60% of patients experience measurable decline in verbal memory (word list learning, story recall); higher risk when preoperative verbal memory is relatively intact (indicating functional hippocampal tissue is being resected)
- Nondominant (usually right) ATL: Mild visual/spatial memory decline in some patients; verbal memory often improves or remains stable
- Naming decline: 25–50% of patients after dominant ATL experience confrontation naming decline (BNT scores); usually mild but can be functionally significant for professionals relying on verbal fluency
- Predictors of memory decline: High preoperative memory performance, normal preoperative MRI (no hippocampal sclerosis), older age at surgery, and less seizure burden preoperatively all predict greater risk of decline
- "Functional adequacy" model: The more functional the hippocampus being resected, the greater the expected decline; conversely, a severely sclerotic hippocampus has little remaining function to lose
- Wada test and fMRI: Used preoperatively to lateralize language and memory; Wada testing involves unilateral carotid amobarbital injection to temporarily inactivate one hemisphere while testing the contralateral hemisphere's memory capacity
Cognitive Benefits of Successful Surgery
Patients who achieve seizure freedom after surgery frequently demonstrate cognitive improvement across multiple domains, particularly attention, processing speed, and executive function. These gains are attributed to the elimination of seizure-related cognitive disruption, reduced ASM burden (many patients can taper to monotherapy or off ASMs entirely), improved sleep, and reduced psychiatric comorbidity. The net cognitive outcome is often positive when surgery achieves seizure freedom, even in the presence of localized memory decline.
Epilepsy & Dementia
There is growing evidence of a bidirectional relationship between epilepsy and dementia. Alzheimer disease increases seizure risk 6–10-fold, and seizures may occur years before clinical dementia becomes apparent. The Atherosclerosis Risk in Communities (ARIC) study found that late-onset epilepsy of unknown etiology significantly predicted subsequent dementia development. Histologic studies of brain tissue from epilepsy surgery resections have demonstrated amyloid and tau deposition in patients without prior neurodegenerative diagnosis. Neuroimaging studies have shown amyloid deposits in patients with drug-resistant epilepsy. Subclinical epileptiform activity has been detected in Alzheimer disease patients using foramen ovale electrodes. These findings have prompted randomized controlled trials (the LEAS trial, the ILiAD trial) investigating whether early ASM treatment can slow cognitive deterioration in patients with Alzheimer disease and epileptiform activity.
| Mechanism | Evidence | Clinical Implication |
|---|---|---|
| Seizure-related hippocampal damage | Recurrent GTC seizures and status epilepticus cause hippocampal neuronal loss; progressive hippocampal atrophy on serial MRI in drug-resistant TLE | Aggressive seizure control may slow cognitive decline; avoid prolonged status epilepticus |
| Amyloid and tau pathology in epilepsy | Histologic amyloid plaques and tau tangles found in temporal lobe resections; amyloid PET positive in some drug-resistant epilepsy patients | Epilepsy may accelerate or be an early manifestation of neurodegenerative pathology |
| Subclinical epileptiform activity in AD | Silent hippocampal seizures detected by foramen ovale electrodes; scalp EEG may not detect these | ASM treatment of subclinical activity may benefit cognition — trials in progress |
| Late-onset epilepsy as dementia predictor | ARIC study: new-onset epilepsy of unknown etiology in older adults predicts subsequent dementia | Cognitive screening and longitudinal monitoring in late-onset epilepsy patients |
| ASM effects on neurodegeneration | Levetiracetam may have anti-amyloid properties (preclinical data); enzyme-inducing ASMs may increase vascular risk | Prefer levetiracetam or lamotrigine in elderly patients with cognitive concerns |
Cognitive Rehabilitation
Cognitive rehabilitation in epilepsy is an emerging field that aims to improve functional cognitive performance through targeted interventions. While evidence remains limited compared to rehabilitation for stroke or traumatic brain injury, several approaches have shown promise in epilepsy populations and should be offered as part of comprehensive epilepsy care.
| Intervention | Target Domain | Evidence Level | Practical Implementation |
|---|---|---|---|
| Compensatory strategies | Memory, organization, daily functioning | Moderate — most practical and widely recommended | Smartphones (calendar, alarms, reminders), pill organizers, written checklists, label systems, consistent routines and environmental cues |
| Attention training | Sustained and divided attention | Low to moderate — computerized training shows modest benefits | Computerized cognitive training programs (Cogmed, Lumosity); structured attention exercises; 20–30 minutes/day, 5 days/week for 5–8 weeks |
| Memory rehabilitation | Encoding and retrieval | Low to moderate | Errorless learning techniques; spaced retrieval practice; visual imagery and association strategies; story method for learning new information |
| Self-management programs | Global cognitive function, seizure management, well-being | Moderate — multimodal programs show the most consistent benefits | HOBSCOTCH program; Managing Epilepsy Well (MEW); integrate seizure management, sleep hygiene, stress reduction, and cognitive strategies |
| Physical exercise | Hippocampal volume, memory, processing speed | Moderate — strong evidence from general population, growing epilepsy-specific data | 150 minutes/week moderate-intensity aerobic exercise; walking, swimming, cycling; may also reduce seizure frequency and improve mood |
| Mindfulness-based interventions | Attention, emotional regulation, subjective cognitive complaints | Low to moderate | Mindfulness-based stress reduction (MBSR); 8-week structured programs; may benefit both cognition and psychiatric comorbidities |
| ASM simplification | All domains | Strong — most effective single intervention for ASM-related cognitive impairment | Switch from topiramate, phenobarbital, or phenytoin to lamotrigine, levetiracetam, or lacosamide; convert from polytherapy to monotherapy when feasible |
| Treatment of comorbid depression | Attention, processing speed, memory | Strong — depression independently impairs cognition | SSRI therapy; CBT; adequate treatment of depression often produces more cognitive improvement than direct cognitive rehabilitation |
Educational & Employment Impact
Epilepsy significantly affects educational achievement and employment across the lifespan. The cognitive consequences of epilepsy create barriers at every stage of education and professional development.
Educational Impact in Children & Adolescents
- Children with epilepsy have lower academic attainment, higher rates of learning disabilities (affecting 20–50%), and greater need for special education services (30–40%)
- Cognitive effects of early-onset epilepsy disrupt the acquisition of foundational academic skills — the earlier the onset and the more frequent the seizures, the greater the academic impact
- Absence epilepsy, despite being considered "benign," can cause significant academic impairment through unrecognized staring episodes during classroom instruction
- ASM side effects (particularly topiramate, phenobarbital) compound academic difficulties through impaired attention and processing speed
- Psychosocial factors — absenteeism due to seizures and medical appointments, social stigma, bullying, and parental overprotectiveness — further limit educational participation
- Individualized Education Programs (IEPs) and 504 Plans provide legal frameworks for classroom accommodations (extended test time, note-taking assistance, permission to leave class during seizures, modified homework expectations)
Employment Impact in Adults
Adults with epilepsy have unemployment rates 2–3 times the general population, even when seizures are well-controlled. Contributing factors include driving restrictions (limiting job options and commuting), stigma and discrimination, cognitive limitations, and the unpredictability of seizures. Many adults with epilepsy are underemployed — working below their educational qualifications and cognitive ability due to employer reluctance and self-imposed limitations.
Workplace accommodations under the Americans with Disabilities Act (ADA) include flexible scheduling, ability to rest during postictal periods, avoidance of certain triggers (flashing lights, extreme sleep deprivation), work-from-home options, and modified job duties during periods of seizure recurrence. Vocational rehabilitation services can assist with job placement, skills training, and employer education. Neuropsychological testing can identify specific cognitive strengths and weaknesses to guide vocational counseling and job matching.
Driving & Cognitive Requirements
Driving involves complex cognitive demands including sustained attention, rapid processing speed, visual-spatial processing, and executive function — domains frequently impaired by epilepsy, ASMs, or both. Beyond the seizure-free interval requirement (3–12 months, varying by US state), cognitive impairment itself may render a patient unsafe behind the wheel even during seizure-free periods. This is particularly relevant for patients on polytherapy with topiramate or sedating ASMs. Neuropsychological testing, driving simulators, and on-road driving evaluations can provide objective data when cognitive fitness to drive is uncertain. Physicians should document discussions about driving restrictions and cognitive safety considerations.
Practical Approach to Cognitive Complaints in Epilepsy
- Step 1 — Identify the complaint: Is it word-finding (topiramate), memory (seizure-related), attention (polytherapy), or global slowing (depression)?
- Step 2 — Review ASM regimen: Consider simplifying to monotherapy; switch from topiramate, phenobarbital, or phenytoin to lamotrigine, levetiracetam, or lacosamide
- Step 3 — Screen for depression and anxiety: NDDI-E, PHQ-9; treat if positive — depression alone can cause significant cognitive impairment
- Step 4 — Assess sleep: Screen for OSA (common in epilepsy); review nocturnal seizure burden; optimize sleep hygiene
- Step 5 — Neuropsychological testing: Objective baseline when diagnosis is uncertain or before/after major treatment changes; essential for surgical candidates
- Step 6 — Optimize seizure control: Recurrent seizures, especially GTC, are the most significant modifiable risk factor for progressive cognitive decline
- Step 7 — Rehabilitate and accommodate: Cognitive rehabilitation strategies, assistive technology, educational accommodations, vocational support
References
- Helmstaedter C, Witt JA. Anti-convulsant drugs and cognition. In: NeuroPsychopharmacotherapy. Springer International Publishing; 2020:1–12.
- Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: a randomized double-blind study. Neurology. 2011;76(2):131–137.
- Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs. 2009;23(2):121–137.
- Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385–407.
- Witt JA, Helmstaedter C. Monitoring the cognitive effects of antiepileptic pharmacotherapy: approaching the individual patient. Epilepsy Behav. 2013;26(3):450–456.
- Gonzalez LM, Wrennall JA. A neuropsychological model for the pre-surgical evaluation of children with focal-onset epilepsy. Seizure. 2020;77:29–39.
- Baxendale S, Thompson PJ. The role of the Wada test in the surgical treatment of temporal lobe epilepsy. Epilepsia. 2005;46(5):802–810.
- Sherman EMS, Wiebe S, Fay-McClymont TB, et al. Neuropsychological outcomes after epilepsy surgery: systematic review and pooled estimates. Epilepsia. 2011;52(5):857–869.
- Johnson EL, Krauss GL, Kucharska-Newton A, et al. Dementia in late-onset epilepsy: the ARIC study. Neurology. 2020;95(24):e3248–e3256.
- Gourmaud S, Shou H, Irwin DJ, et al. Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy. Brain. 2020;143(1):191–209.
- Vossel K, Ranasinghe KG, Beagle AJ, et al. Effect of levetiracetam on cognition in patients with Alzheimer disease. JAMA Neurol. 2021;78(11):1345–1354.
- Lam AD, Deck G, Goldman A, et al. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer disease. Nat Med. 2017;23(6):678–680.
- Ettinger AB. Psychotropic effects of antiepileptic drugs. Neurology. 2006;67(11):1916–1925.
- Calik M, et al. Assessment of temporal changes in cognitive effects induced by antiseizure medications in epilepsy patients. Epilepsy Behav. 2024;161:110098.
- Keezer MR. Epilepsy comorbidities. Continuum (Minneap Minn). 2025;31(1):232–246.
- Bensalem-Owen MK. Sexual and reproductive health in the management of epilepsy. Continuum (Minneap Minn). 2025;31(1):214–231.
- Hickman LB, Stern JM, Silverman DHS, Salamon N, Vossel K. Clinical, imaging, and biomarker evidence of amyloid- and tau-related neurodegeneration in late-onset epilepsy of unknown etiology. Front Neurol. 2023;14:1241638.
- Sillanpaa M, Anttinen A, Rinne JO, et al. Childhood-onset epilepsy five decades later: a prospective population-based cohort study. Epilepsia. 2015;56(11):1774–1783.
- Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016;15(1):106–115.
- Nadkarni S, Devinsky O. Psychotropic effects of antiepileptic drugs. Epilepsy Curr. 2005;5(5):176–181.